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Objective: This study prospectively assessed the diagnostic accuracy of a novel bilateral photoplethysmography toe pulse
measurement technique for the detection of significant lower limb peripheral arterial disease.
Method: Bilateral photoplethysmography toe pulse measurements were compared with the ankle-brachial pressure index
(ABPI) gold standard reference. Pulse wave analysis techniques extracted timing, amplitude, and shape characteristics for
the great toes and their right-to-left side differences. These characteristics were compared with previously obtained
normative ranges, and the accuracy was assessed for all significant disease (ABPI <0.9) and higher-grade disease (ABPI
<0.5). Measurements were collected in a controlled environment within a tertiary vascular surgical unit for 111 subjects
(age range, 42-91years), of whom 48 had significant lower limb peripheral arterial disease and 63 were healthy. Subjects
were matched in age, sex, height, body mass index, and heart rate. Diagnostic performance was assessed using diagnostic
sensitivity, specificity, accuracy, negative-predictive and positive-predictive value, and the  statistic representing
agreement between techniques beyond chance.
Results: The degree that pulse shape fell beyond the normal range of normalized pulse shapes was at the threshold of
substantial to almost perfect agreement compared with ABPI for significant disease detection (diagnostic accuracy, 91%
[  0.80]; sensitivity, 93%; specificity, 89%), and with 90% accuracy (  0.65) for higher-grade disease detection. Pulse
transit time differences between right and left toes also had substantial agreement with ABPI, with diagnostic accuracy
of 86% for significant disease detection (pulse transit time to pulse foot [  0.71] and to pulse peak [  0.70]) and
reached at least 90% for these for the higher-grade disease. The performance ranking for the different pulse features
mirrored an earlier pilot study. With the shape and pulse transit time measurements, the negative-predictive values of the
5% disease population screening-prevalence level were at least 99% and had positive-predictive values of at least 98% for
the 90% disease-prevalence level for vascular laboratory referrals.
Conclusion: This simple-to-use technique could offer significant benefits for the diagnosis of peripheral arterial disease in
settings such as primary care where noninvasive, accurate, and diagnostic techniques not requiring specialist training are
desirable. Improved diagnosis and screening for peripheral arterial disease has the potential to allow identification and
risk factor management for this high-risk group. ( J Vasc Surg 2008;47:794-802.)Peripheral arterial occlusive disease (PAD) is a manifes-
tation of widespread atherosclerosis and as such is also
associated with an increased risk of coronary artery disease
and stroke.1,2 The risk of cardiac death in patients with
intermittent claudication (IC) is three to four times greater
than those without IC, and accounts for as many as 75% of
all deaths in this group.1,3 Classic risk factors such as
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794smoking, hypertension, hypercholesterolemia, and diabe-
tes mellitus are each commonly seen and require the same
aggressive treatment as for patients with coronary or cere-
brovascular disease.4 The prevalence of PAD increases with
age, especially from the fourth or fifth decade of life.5-8
Selvin and Erlinger9 have reviewed studies of PAD preva-
lence in the United States that used similar diagnostic
criteria and found a range of 3% to 30%. Their own data
showed that 4.3% of subjects aged 40 years, or about 5
million people, had significant disease, rising to approxi-
mately 15% for those aged 70 years.
The diagnosis of PAD can be made by clinical criteria,
but other conditions such as musculoskeletal, spinal dis-
ease, and venous disease may also produce similar exercise-
induced symptoms. In addition, many patients do not
report typical exercise-induced symptoms because of asso-
ciated immobility or limitations owing to conditions such
as angina or dyspnea. A confirmatory test is required to
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to date, the most validated is the ankle-brachial pressure
index (ABPI).2,10 In the future, there may also be a need
for community screening for PAD to identify asymptomatic
at-risk individuals, because PAD severity as assessed by the
ABPI appears to predict death and cardiovascular risk, even
in asymptomatic patients.2
The ABPI technique has limitations despite its apparent
simplicity. Our own observations and those of experienced
vascular nurse specialists is that significant uncertainty can
exist both in the community and in nonvascular hospital
environments about the correct measurement technique
required to obtain an accurate ABPI. Furthermore, an
ABPI examination can take 10 minutes to perform, lim-
iting its value for routine vascular screening in a primary
care setting.
An ideal vascular screening technology should be low-
cost, quick, reliable, repeatable, noninvasive, and simple to
operate. One technique that has this potential is the optical
pulse technology, photoplethysmography (PPG),11-18
which detects changes in the blood volume in the micro-
vascular bed of tissue. Its waveform comprises a pulsatile
(“AC”) physiologic waveform attributed to cardiac syn-
chronous changes in the blood volume with each heart beat
that is superimposed on a slowly varying (“DC”) baseline,
with various lower-frequency components attributed to
respiration, sympathetic nervous system activity, and ther-
moregulation.19 Disease detection with PPG is possible
because the peripheral AC pulse usually becomes damped,
delayed, and diminished with increasing severity of vascular
disease.12,20-22 It is important to note that we did not set
out to prove that PPG pulse was superior to ABPI measure-
ments in either accuracy or speed, but rather to ascertain
the level of agreement between these two technologies to
assess the potential and feasibility of a larger community-
based study.
We have previously published a pilot study14 in which
we retrospectively defined normative PPG pulse ranges for
subjects aged 40 years and quantified the degree the
peripheral pulse became delayed, damped, and diminished
for different grades of vascular disease. Our pilot data, using
ABPI as a diagnostic reference, indicated that pulse shape
contained the greatest diagnostic information for arterial
disease detection, although simple timing differences be-
tween the right and left toe pulses were also found to be
clinically useful.
The aims of this study were to prospectively determine
the diagnostic sensitivity, specificity, and accuracy of bilat-
eral PPG pulse measurements for detecting lower limb
PAD in a mixed group of healthy and PAD subjects aged at
40 years and also to determine the corresponding posi-
tive-predictive values (PPV) and negative-predictive values
(NPV) for the range of disease prevalence.
MATERIAL AND METHODS
Subjects. The study population included a mixture of
individuals aged 40 years with healthy arteries and those
with significant PAD. We aimed for a similar number ofsubjects overall and also a similar proportion having signif-
icant PAD (ie, close to 40%), as in the recruitment in the
pilot study. In this study, participants were recruited from
the University of the Third Age (U3A, Sunderland
Branch), the Institution of Electrical Engineers (Retired
Members Section), Freeman Hospital staff, and the North-
ern Vascular Centre. The research study was approved by
the Local Research Ethics Committee. All subjects gave
written informed consent.
Exclusion criteria were an obvious cardiac arrhythmia that
significantly limited the number of heart beats available for
pulse wave analysis, lower limb amputation, vasculitis, signifi-
cant movement artefact (eg, due to limb tremor), cardiac
pacemaker, skin problems (eg, cuts or bruising at a measure-
ment site or photosensitive skin), or Raynaud phenomenon.
We did not specifically exclude those with hypertension, dia-
betes mellitus, hypercholesterolemia, chronic renal failure, or
ischemic heart disease because these are all relevant to the
atherosclerotic phenotype.
Subjects’ height and weight were measured, providing
the body mass index (BMI). They were asked about any
nicotine use or smoking history, if they had been diagnosed
with diabetes mellitus (noninsulin dependent or insulin
dependent), chronic renal failure, or ischemic heart disease,
and if they were being treated for hypertension or hyper-
cholesterolemia. Claudication symptoms suggestive of
those specified in the Edinburgh Claudication Question-
naire23 were also noted.
Pulse and ankle-brachial pressure index diagnostic
reference measurements and their analysis. Physio-
logic measurements were made in a warm, temperature-
controlled room (24° 1°C), and at least 10 minutes were
given for thermal acclimatization and relaxation. Measure-
ments were made with subjects in the supine position; first,
the ABPI measurements for both legs as the gold standard
reference for the presence of PAD (ie, 0.9), and then the
bilateral PPG great toe pulse measurements. The ABPI was
calculated using highest of the right and left ankle systolic
blood pressures (ie, for dorsalis pedis and posterior tibial
arteries) divided by the highest of the right and left arm
brachial systolic pressures. The analysis also included a
disease subclassification for higher-grade disease of ABPI
0.5. We did not seek to determine the location of disease
in those with an abnormal ABPI.
Unlike ABPI, which compares ankle level with an arm
control measurement, bilateral PPG can be used to refer-
ence one side of the body (right great toe) with the con-
tralateral side (left great toe) to detect PAD. In healthy
subjects, the blood pressure, height, and heart rate are
common to both sides of the body at rest, resulting in no
net differences between the legs. A significant arterial ste-
nosis will delay or dampen the pulse arriving at the foot,
resulting in pulse features that are outside the expected
normal ranges and corresponding bilateral dissimilarity be-
tween the toes (Fig 1, a). In completely symmetrical PAD,
the differences between sides can be small and so disease
will not be detected unless individual measurement sites are
also compared against the normal ranges.
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a concept prototype, and is not currently available commer-
cially. It was the winner of two recent innovations awards,
the UK National Health Service Health and Social Care
Award for Innovative Technology 2006, and the Institute
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Fig 1. The (a) panel shows the great toe pulses from a patient
with unilateral peripheral arterial disease (PAD). The right leg has
normal ankle-brachial pressure index (ABPI), and the ABPI is
0.5 for the left leg, resulting in significant damping on the left
side and delayed relative to the right side. ECG, Electrocardio-
gram. The (b) panel shows pulse characterization in the pulse
transit time (PTT) from ECG R wave to pulse foot (PTTf) and to
pulse peak (PTTp) and the foot-to-peak rise time (RT) and ampli-
tude normalized to photoplethysmography amplifier gain. For
each heartbeat, the pulse shape is normalized in height and width,
for pulse foot (1), peak (2), and foot (3) landmarks. The average
time, amplitude, and normalized shape waveforms are then com-
puted from a total of 60 consecutive good-quality heartbeats. The
(c) panel shows the average normalized pulse shapes for the patient
with unilateral PAD in panel (a) above. Finally, a shape index
measure quantifies the total area of the pulse falling outside the
normal range of normalized shape profiles.14 In healthy subjects,
the shape index is 0 or close to 0; however, pulses from vascular
patients should have significantly greater values to reflect the
degree of shape distortion in PAD.of Physics and Engineering in Medicine Manufacturers’Award 2007. The system has been previously de-
scribed.12,14 Briefly, it simultaneously acquires bilateral
PPG great toe pulses using electronically matched pairs of
right and left pulse amplifiers of bandwidth (range, 0.15-20
Hz) with data recorded to a computer for 150 seconds
using 16-bit analogue-to-digital conversion at a sampling
rate of 2500 Hz. The gain of each pulse amplifier channel
was also recorded for subsequent analysis. In addition, a
single lead diagnostic bandwidth electrocardiogram (ECG)
was recorded to provide a cardiac timing reference.
Pulses were characterized (Fig 1, b) in terms of timing
in seconds (pulse transit time from ECG R wave to pulse
foot [PTTf] and to pulse peak [PTTp] and the foot-to-peak
rise time), foot-to-peak amplitude [AMP] calibrated by
normalizing with the respective PPG amplifier gain setting,
and normalized pulse shape waveform of height between 0
(pulse foot) and 1 (pulse peak) and a width of unity with
100 equally spaced points computed using cubic spline
interpolation (Fig 1, c).14 Pulse shape normalization has
been used in earlier studies so that pulse shapes can be fairly
compared between subjects with different heart rates or
different pulse heights, or both. Comparisons between the
great toes formed the bilateral comparisons (ie, referenced
within subjects). Bilateral differences in toe timing and
shape waveforms were obtained from their absolute differ-
ences. Bilateral amplitude differences were represented us-
ing the ratio of the largest to smallest pulse size.
Because PPG characteristics vary slightly from beat-to-
beat then the average time, amplitude and shape waveforms
were computed for the toes of each subject from a total of 60
consecutive good-quality heartbeats from the 150-second
recording. In a quality control stage, a single operator
(J. A.) manually assessed the ECG and pulse traces offline,
identifying and then marking and excluding ventricular
ectopic beats, movement artefact, and noisy pulses from the
pulse averaging analysis.
An objective shape index measure quantified the total
area of the pulse falling outside the normal range of nor-
malized shape profiles. In healthy subjects, the shape index
is 0 or close to 0; however, pulses from vascular patients
with PAD should have significantly greater values to reflect
the degree of shape damping or loss of pulsatility. The
system output and diagnostic accuracy of PPG measure-
ments for detecting lower limb PAD was determined pro-
spectively by comparing patient toe pulse data with our
published normative ranges14 for timing, amplitude, and
shape characteristics as well as their absolute bilateral dif-
ferences, referenced to the ABPI. These data were not
subjectively interpreted: they were either normal (ie, within
the normal range) or were abnormal (ie, outside the normal
range).
Statistical analysis. Clinical and pulse data were sum-
marized using median values and interquartile ranges, with
differences between the subject groups tested using the
Mann-Whitney test. The difference in proportions between
the groups was tested using the 2 test. A value of P  .05
was used as the level of statistical significance. The diagnos-
tic performance statistics were calculated with contingency
tionna
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 statistic for each pulse measure, references to ABPI.24,25
The  statistic represents the amount of agreement beyond
chance with defined categoric ranges, with0.80 as almost
perfect agreement; 0.61 to 0.80, substantial; 0.41 to 0.60,
moderate; 0.21 to 0.40, fair; 0.01 to 0.20, slight; and 0 as
chance agreement.26 Performance was ranked in order of
 values.
The prevalence-adjusted PPVs and NPVs were calcu-
lated using two equations24 in which PPV and NPV are
derived from the number of true positives (proportion of
positive predictions that have PAD by the gold standard
definition) and true negatives (proportion of negative pre-
dictions that do not have PAD by the gold standard defi-
nition), for disease prevalence (pr) in the range 0.01 (1%) to
1 (100%): NPV (1 pr) Sp/{[(1 pr) Sp]	 [(1
Se)  pr]} and PPV  pr  Se/{(pr  Se) 	 [(1  pr) 
(1  Sp)]}, with Sp, specificity; and Se, sensitivity as propor-
tions.
Predictive values were also calculated for the predefined
clinical scenarios of (1) PAD in a general population9
(disease prevalence, 5%) and (2) subjects referred to a
specialist vascular measurement laboratory for PAD assess-
ment (estimated disease prevalence, 90%; unpublished au-
dit data). Predictive values were determined for the pulse
features that were the most reliable at detecting ABPI-
Table I. Demographics for the 111 subjects in the prospe
Variable
Ank
0.9 both legs
Race, white 63 (100)
Age, years 69 (61-75)
Sex, male 37 (59)
Height, m 1.68 (1.60-1.75)
Weight, kg 75.0 (68.3-82.8)
Body mass index, kg/m2 26.2 (24.1-28.3)
Heart rate, beats/min 66 (63-74)
Systolic BP, mm Hg 150 (130-158)
Hypertension treatment 23 (37)
Smoking history 21 (33)
Current 9
Ex-smoker 12
Hypercholesterolemia 32 (51)
Diabetes 5 (8)
Noninsulin dependent 5
Insulin dependent 0
Chronic renal failure 2 (3)
Ischemic heart disease 7 (11)
ABPI assessment 1.11 (1.03-1.21)
Subjects ABPI 1.3 8 (13)
Diabetes 1
Renal 2
Claudication symptomsc 6 (10)
ABPI, Ankle-brachial pressure index; BP, blood pressure; NV, the 2 test w
aData are expressed as numbers (%) and median (interquartile range) values
bStatistical significance set at P  .05.
cSuggestive of the symptoms specified in the Edinburgh Claudication Quessignificant PAD (ie, using the highest  statistic).RESULTS
A total of 111 white subjects (age range, 42-91 years)
were included in the prospective study. The analysis ex-
cluded one subject because of significant movement arte-
fact and noise throughout the recording, giving 222 legs
for subsequent analysis. By ABPI classification, 63 subjects
had healthy arteries and 48 subjects (43%) had significant
vascular disease. Fourteen subjects (13%) had higher-grade
disease in at least one leg, and 34 (31%) had significant
bilateral disease.
The demographics for the two subject groups are re-
ported in Table I,23 with groups matching for age, sex,
height, weight, BMI, and heart rate. There was only a
marginally higher arm systolic blood pressure in those with
significant PAD (P .03), but an increased proportion was
being treated for hypertension (P  .04). There were no
significant differences between the groups in the propor-
tion having diabetes or being treated for hypercholesterol-
emia. Those with PAD also had a significantly greater
proportion of smokers (P  .007) and ischemic heart
disease (P  .01). Two subjects in each group had chronic
renal failure. As expected, the ABPI was significantly lower
in the PAD group (P .0001) and with a greater incidence
of claudication symptoms (P  .001). Eight subjects had
raised ABPIs of 1.3 in at least one leg consistent with
calcification of the peripheral arteries, although three of
bilateral toe photoplethysmography study
chial pressure index a
Pb0.9 in at least 1 leg
48 (100) . . .
69 (64-75) .43
25 (52) .71
1.67 (1.59-1.72) .25
75.0 (63.8-86.0) .99
26.6 (24.2-30.6) .33
68 (60-78) .53
153 (139-175) .03
35 (73) .04
39 (81) .007
22 . . .
17
40 (83) .10
11 (23) .06
8
3
2 (4) NV
17 (35) .01
0.65 (0.53-0.81) .0001
0 (0) NV
0
0
46 (96) .001
valid.
ire.23ctive
le-bra
as not
.these were either diabetic or had renal failure.
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amplitude, and shape pulse features in healthy arteries and
how they change with arterial disease. There are significant
increases in all three pulse timing measurements represent-
ing waveform delay (PTTf) and damping (PTTp and rise
time) and also dissimilarity between the foot and peak
landmarks between the legs. The pulse amplitude was
significantly lower in PAD, but there was clear overlap with
healthy subjects, although the right-to-left side ratio of
pulse amplitudes did not significantly differ with disease.
The shape index produced a clear separation between PAD
and healthy subjects. These data ranges and differences
between healthy subjects and vascular patients mirror and
confirm the findings from our pilot study.
The diagnostic performance for the prospective assess-
ment is reported in Table III. The shape index gave the
highest accuracy for individual legs at 90.5% ( 0.80) and at
the top limit of substantial agreement with ABPI, and PTTf
had the highest accuracy for absolute bilateral differences
between legs at 85.6% (  0.71) substantial agreement with
ABPI. These findingsmirror the pilot study (Table IV), where
pulse feature performance was ranked, from highest to lowest
, in exactly the same order: shape index, rise time, and PTTp
for the detection of significant PAD in individual legs. Slight
differences occurred in the second- and third-place order in
performance for the higher-grade disease; for individual legs,
shape index, rise time, and PTTp for the prospective assess-
ment; and shape index, PTTp, and rise time for the pilot
assessment. For bilateral difference comparisons, the pulse
transit time performed the best in both studies, although with
time to peak and time to foot interchanged with marginal
differences in  between them.
Overall, this study has shown substantial agreement
between PPG and the gold standard, with accuracies of
between 86% and 92%, depending on site comparison and
disease severity subclassification. The higher-grade disease
could be detected with a sensitivity of between 92% and
Table II. Photoplethysmography toe pulse features from
disease using ankle-brachial pressure index
Variable Normal (ABPI
Individual legs
PTTf, ms 259 (242-2
PTTp, ms 493 (465-5
Rise time, ms 234 (215-2
AMP, V normalized 0.17 (0.07-0
SI, normalized area units 0.0 (0.0-0.
Bilateral differences between legs
PTTf, ms 5.1 (2.1-11
PTTp, ms 12.9 (6.0-27
Rise time, ms 10.8 (4.8-21
AMP, ratio 1.5 (1.3-2.
SI, normalized area units 0.0 (0.00-0
ABPI, Ankle-brachial pressure index; AMP, amplitude normalized to gain s
PTTp, pulse transit time to peak of pulse; SI, shape index.
aThe median (interquartile ranges) are shown.
bMann-Whitney.100% using pulse transit time measures. Pulse amplitude,however, has been ranked consistently as a poorly discrim-
inating measure.
A scatter plot is shown in Fig 2, A for the best
performing measure for individual legs, the shape index.
In a small number of legs, the false-positive values can be
seen where the ABPI is 0.9 but with high shape index
values, with overlap clearer between the borderline ABPI
levels 0.8 to 1.0. Furthermore, the general trend is for a
negative correlation with increasing severity of disease.
Fig 2, B shows the slight improvement in accuracy that
was obtained when the maximum shape index value for
each patient is plotted against the corresponding leg
ABPI. This approach, on a patient-by-patient screening
basis, gave an overall accuracy of close to 95% (ie, almost
perfect  agreement with ABPI).
The bilateral timing differences for PTTf between legs
are shown in Fig 3, A. Cases can be seen where timing
differences between the right and left toes in subjects with
significant disease is small for when there are equally dis-
torted pulses and no relative delay between the legs. This
limits the sensitivity of the test, particularly in the subjects
with lower-grade disease. Finally, Fig 3, B emphasizes the
degree of bilateral similarity across the study ABPI range for
bilateral pulse transit timing characteristics by comparing
PTTf and PTTp side differences.
The diagnostic performance for the prevalence adjusted
PPV and NPV values of the test is summarized in Fig 4, with
the relationships between predictive value and prevalence
clearly nonlinear. The NPV and PPV values are both shown
for shape index (individual legs) and for PTTf (bilateral
difference) comparisons. The NPV and PPV are high
(95%) for prevalence levels 20% and for 80%, respec-
tively. The predictive values at the specific prevalence levels
of 5% (general population screening) and 90% (vascular
measurement laboratory referrals), gave NPVs of at least
99% and PPVs of at least 98%, respectively. In contrast,
their respective PPV and NPV were poor at these preva-
subjects categorized by degree of peripheral arterial
)a PAD (ABPI 0.9)a Pb
288 (269-334) .0001
611 (551-715) .0001
325 (280-372) .0001
0.06 (0.02-0.12) .0001
5.7 (2.0-9.3) .0001
45.3 (21.5-75.0) .0001
99.4 (53.6-137.1) .0001
48.3 (26.3-87.8) .0001
1.9 (1.4-2.7) .08
0.47 (0.04-1.92) .0001
; PAD, peripheral arterial disease; PTTf, pulse transit time to foot of pulse;111
0.9
73)
21)
55)
.34)
0)
.6)
.5)
.4)
5)
.02)
ettinglence levels.
etting
lse; PT
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This prospective assessment has quantified the diagnos-
tic performance of bilateral PPG technology for detecting
lower limb PAD. A comparison of prospective with pilot
assessments showed very similar performances and has con-
firmed that shape can provide the best diagnostic informa-
Table III. Summary of diagnostic performance for the pro
Variable Sensitivity, % Specifici
Individual legs
ABPI 0.9
Shape index 92.7 89.3
Rise time 84.2 82.1
PTTp 69.5 83.6
PTTf 35.4 84.3
AMP 34.2 84.3
ABPI 0.5
Shape index 95.0 89.3
Rise time 100.0 82.1
PTTp 85.0 83.6
PTTf 75.0 84.3
AMP 60.0 84.3
Bilateral differences
ABPI 0.9
PTTf 83.3 87.3
PTTp 77.1 92.1
Rise time 62.5 93.7
Shape index 58.3 88.9
AMP 20.1 87.3
ABPI 0.5
PTTp 92.3 92.1
PTTf 100.0 87.3
Shape index 78.6 88.9
Rise time 64.3 93.7
AMP 28.6 87.3
ABPI, Ankle-brachial pressure index; AMP, amplitude normalized to gain s
of pulse.
Table IV. A summary of the three leading diagnostic puls
study in 107 subjects14 are ranked for 
Variable Sensitivity, % Specifici
Individual legs
ABPI 0.9
Shape index 88.9 90.6
Rise time 75.9 88.8
PTTp 64.8 91.3
ABPI 0.5
Shape index 100.0 90.6
PTTp 86.4 91.3
Rise time 86.4 88.8
Bilateral differences
ABPI 0.9
PTTp 75.0 93.3
PTTf 71.9 93.3
Rise time 56.3 94.7
ABPI 0.5
PTTf 92.9 93.3
PTTp 92.9 93.3
Rise time 64.3 94.7
ABPI, Ankle-brachial pressure index; PTTf, pulse transit time to foot of pution. This prospective assessment was essential for the val-idation of the technology for routine clinical use. We have
also investigated the expected diagnostic utility of the tech-
nique in two dichotomous clinical settings: the screening of
subjects aged40 years and the testing of patients referred
to a vascular assessment laboratory. These have quite dif-
fering levels of disease prevalence that affect the test predic-
tive bilateral photoplethysmography study, ranked by 
Accuracy, %   Class
90.5 0.80 Substantial
82.9 0.64 Substantial
78.4 0.53 Moderate
66.2 0.21 Fair
65.8 0.20 Slight
90.0 0.65 Substantial
84.4 0.54 Moderate
83.8 0.48 Moderate
83.1 0.44 Moderate
81.3 0.34 Fair
85.6 0.71 Substantial
85.6 0.70 Substantial
80.2 0.58 Moderate
75.7 0.49 Moderate
58.6 0.09 Slight
92.1 0.76 Substantial
89.6 0.71 Substantial
87.0 0.61 Substantial
88.3 0.60 Moderate
76.6 0.17 Slight
; PTTf, pulse transit time to foot of pulse; PTTp, pulse transit time to peak
tures from the pilot bilateral toe photoplethysmography
Accuracy, %   Class
90.2 0.75 Substantial
85.5 0.63 Substantial
84.6 0.58 Moderate
91.8 0.70 Substantial
90.7 0.64 Substantial
88.5 0.58 Moderate
87.9 0.70 Substantial
86.9 0.68 Substantial
83.2 0.56 Moderate
93.3 0.77 Substantial
93.3 0.77 Substantial
89.9 0.61 Substantial
Tp, pulse transit time to peak of pulse.spec
ty, %e fea
ty, %tive values. Here, depending on the setting, the different
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diagnostic accuracy, for example, by selecting specific pulse
features individually or in combination. Accuracy could
also be optimized in future studies for the small percentage
of patients who have completely symmetrical PAD where
bilateral differences alone are likely to miss disease, for
example, by logically combining classifications from bilat-
eral timing differences with the shape index in either toe.
The diagnosis of PAD can also be assessed using for-
malized questionnaires, such as the World Health Organi-
zation Intermittent Claudication questionnaire or the Rose
questionnaire. However, in the German Epidemiological
Study on Ankle Brachial Index (GetABI) study of 6880
primary care patients aged 65 years, 18% had PAD de-
fined by an ABPI0.9, but only 11% had classic symptoms
of the disease according to the WHO IC questionnaire.27
Fig 2. Summary of the shape index measurements plotted against
the ankle-brachial pressure index (ABPI). A, Shape index with
diagnostic accuracy close to 91%. Two shape index values lie
beyond the axes (values close to 35) for two of the vascular patients
where a toe pulses could not be detected in one of their legs. B, A
comparison of improved diagnostic accuracy when the maximum
shape index value for each patient is plotted against the corre-
sponding ABPI for that leg, giving an accuracy close to 95%.Similarly only 8.7% of patients in the PAD Awareness, Riskand Treatment: New Resources for Survival (PARTNERS)
study had typical symptoms as defined by the Rose claudi-
cation questionnaire.28 These data confirm that the diag-
nosis cannot be made reliably on clinical symptoms alone.
As a confirmatory test, the measurement of ABPI has
become the accepted measure of choice in both clinical
practice and epidemiologic studies. These questionnaires,
or elements of them, could be incorporated into the instru-
ment to shift prevalence levels to optimize predictive val-
ues; for example, close to 50% to give predictive values both
close to 90% for the shape index measure.
As with most gold standards in vascular measurement,
the ABPI is also not perfect. It has been reported to be 95%
sensitive and 99% specific for PAD when a 0.9 cut-off level
from resting measurements is used.29,30 The reduced gold
standard sensitivity could, however, help to partly explain
the number of false-positive classifications seen in our re-
Fig 3. A, Absolute bilateral differences in pulse transit time
(PTT) from R wave to pulse foot (PTTf) with diagnostic accuracy
close to 86%. B, A comparison of bilateral differences in peak pulse
transit time (PTTp) and PTTf, plotted against the ankle-brachial
pressure index (ABPI) gold standard reference. The extent of
bilateral similarity in healthy subjects can be seen. Note: two points
lie beyond the axes of this figure for two patients where a pulse
signal could not be detected on one of their great toes.sults (Fig 2).
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by the inclusion of a standard treadmill exercise test and
postexercise ABPI, and future studies should consider in-
cluding this in their protocol.31 Its accuracy can also be
reduced in patients with calcified blood vessels, such as in
those with diabetes or chronic renal failure, although this
did not appear to be a problem in our study because less
than half of the 7% subjects who had a raised ABPI of1.3
in either leg had these diseases. We do, of course, recognize
that calcification would be an issue for general PAD screen-
ing, and it would therefore be appropriate to evaluate this
further in future studies. Future research could also assess
modified ABPI calculations that have recently been re-
ported to improve the sensitivity of PAD detection.32
Other diagnostic references that could have been used
to evaluate the PPG technology include color-coded du-
plex ultrasound imaging with 83% agreement with resting
ABPI31 and also contrast-enhanced magnetic resonance
angiography.33 Although these imaging-based assessments
are costly and resource intensive, they would have the
advantage over ABPI in that they can provide some addi-
tional information about disease location.
The PPG assessments presented in this report may be
clinically valuable in helping to assess the future risk of death
due to myocardial infarction and stroke by detecting the
presence of PAD.2 This risk is also related in a gradatedway to
the actual ABPI level. As a result, the presence of PAD has
been designated as a coronary disease equivalent in cardiovas-
cular treatment guidelines.34 This has prompted interest in
Fig 4. Relationship between the test negative-predictive values
(NPV) and positive-predictive values (PPV) adjusted for disease prev-
alence for both shape index (SI) and also bilateral differences in pulse
transit time (PTT) fromRwave to pulse foot (PTTf). The two specific
study prevalence levels are marked at 5% (general screening preva-
lence) and at 90% (vascular measurement laboratory referral preva-
lence). At these levels SI (sensitivity, 92.7%; specificity, 89.3%) re-
sulted in an NPV of 99.6% (PPV, 31.3%) and PPV of 98.7% (NPV,
57.6%), respectively. Bilateral differences in PTTf (sensitivity, 83.3%;
specificity, 87.3%) resulted in an NPV of 99.0% (PPV, 25.7%) and
PPV of 98.3% (NPV, 36.7%), respectively.the use of ABPI not just to confirm a clinical diagnosis ofsymptomatic PAD but also to detect subclinical disease in
order to identify individuals who may benefit from important
risk-lowering strategies such as the use of antiplatelet agents
and statin drugs.28 Evidence exists that these patients cur-
rently receive less treatment than those with cardiac disease,
even though they have a similar risk profile.35
Measuring the ABPI for routine PAD screening in a
community setting is limited because it can take 10
minutes to complete, requires the subject to be rested, and
also requires some skill to perform. In this study, we did not
formally compare the times taken to complete ABPI and
PPG assessments. Although a concept prototype pulse sys-
tem was used in this study, it typically took no more than 5
minutes to complete a PPG measurement and approxi-
mately 5 minutes to complete the analysis with a manual
trace quality-checking stage. A fully automated and well-
designed clinical version of the pulse technology could,
however, easily offer a result within a few minutes.
Some potential limitations exist with PPG-based mea-
surements, including a low ambient temperature in which
the toe blood vessels vasoconstrict resulting in very small
pulse amplitudes. A measurement dominated by noise,
smoking, and caffeine can also affect the blood vessels and
so patients should be asked to refrain from these before
their test. Vasomotor reactivity disorders could also affect
the pulse waveform shape and so these would be assessed as
a specific group; for example, in this study we specifically
excluded patients with Raynaud phenomenon. Neverthe-
less, the potential for quick assessments that have substan-
tial agreement with ABPI could offer considerable advan-
tages for the screening of PAD in primary care. This
technology now needs to undergo full and formal clinical
evaluation in this clinical setting.
CONCLUSION
We have shown that the pulse shape-related shape
index measure has the best diagnostic performance, dem-
onstrating that the degree of pulse distortion with PAD can
provide the greatest diagnostic information. Furthermore,
simple pulse transit time differences between right and left
sides came a close second in performance tables, especially
for higher-grade disease. The NPV for the vascular screen-
ing of subjects aged 40 years was at least 99%, giving
confidence that a patient’s lower limb arteries are likely to
be healthy if the test result is negative. The PPV for vascular
measurement laboratory referrals was at least 98%, giving
confidence that the patient has significant disease if the test
result is positive.
The results from this prospective assessment mirror the
findings from the earlier pilot study, proving the potential
power of the simple-to-perform and low-cost technique for
routine vascular screening assessments. These data enable
us to move to the next stage of technology evaluation, with
its assessment in a primary care setting on many thousands
of patients. Ultimately, such pulse assessments could im-
prove the management of patients with vascular diseases by
giving accessible and timely feedback to patients and their
JOURNAL OF VASCULAR SURGERY
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cardiovascular disease.
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